Skip to main content
PMC home page
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2021 Sep 10;11:697967. doi: 10.3389/fonc.2021.697967

The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy

Hannah Zaryouh 1,*,†, Ines De Pauw 1,†, Hasan Baysal 1, Patrick Pauwels 1,2, Marc Peeters 1,3, Jan Baptist Vermorken 1,3, Filip Lardon 1,‡, An Wouters 1,‡
PMCID: PMC8462273  PMID: 34568028

Abstract

The epidermal growth factor receptor (EGFR) is a therapeutic target in head and neck squamous cell carcinoma (HNSCC). Resistance to EGFR-targeted therapies, such as cetuximab, poses a challenging problem. This study aims to characterize acquired cetuximab resistance mechanisms in HNSCC cell lines by protein phosphorylation profiling. Through this, promising combination treatments can be identified to possibly overcome acquired cetuximab resistance in HNSCC. Protein phosphorylation profiling showed increased phosphorylation of Akt1/2/3 after cetuximab treatment in acquired cetuximab resistant cells compared to cetuximab sensitive cells, which was confirmed by western blotting. Based on this protein phosphorylation profile, a novel combination treatment with cetuximab and the Akt1/2/3 inhibitor MK2206 was designed. Synergy between cetuximab and MK2206 was observed in two cetuximab sensitive HNSCC cell lines and one acquired cetuximab resistant variant in simultaneous treatment schedules. In conclusion, this study demonstrates that increased Akt1/2/3 phosphorylation seems to be characteristic for acquired cetuximab resistance in HNSCC cell lines. Our results also show an additive to synergistic interaction between cetuximab and MK2206 in simultaneous treatment schedules. These data support the hypothesis that the combination of cetuximab with PI3K/Akt pathway inhibition might be a promising novel therapeutic strategy to overcome acquired cetuximab resistance in HNSCC patients.

Keywords: PI3K/Akt pathway, cetuximab, EGFR, HNSCC, Akt inhibitor, resistance

Introduction

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer type worldwide and remains one of the most challenging malignancies to treat (1, 2). Through our increasing knowledge regarding the molecular biology of HNSCC, several therapeutic strategies have been developed. The introduction of targeted therapies that inhibit oncogenic signaling pathways, as well as the development of immunotherapies that activate a patient’s immune system are now at the forefront of personalized medicine in cancer treatment.

Over the past decades, research has revealed that the epidermal growth factor receptor (EGFR, HER1) plays an integral role in the tumorigenesis of HNSCC. Increased or sustained activation of the EGFR signaling pathway can induce malignant transformation through sustained signaling for cell proliferation, anti-apoptotic signaling, angiogenesis and metastasis (3). Furthermore, EGFR is highly expressed in a wide range of malignancies, including HNSCC. As a result, EGFR is considered as a compelling drug target (3, 4).

In 2006, the anti-EGFR monoclonal antibody (mAb) cetuximab, was approved by the Food and Drug Administration (FDA) in combination with radiotherapy for locoregionally advanced HNSCC (median overall survival (OS) of 4.1 years versus 2.4 years with radiotherapy alone) and in combination with platinum-based therapy and infusional 5-fluorouracil (EXTREME regimen) for the first-line treatment of patients with recurrent/metastatic (R/M) HNSCC (median OS 10.1 months versus 7.4 months with chemotherapy alone) (5–7). To date, the therapeutic landscape of HNSCC is changing as the anti-programmed death-1 (PD-1) immune checkpoint inhibitor pembrolizumab has been FDA-approved in June 2019 as a first-line treatment of R/M HNSCC. The Keynote-048 study demonstrated that pembrolizumab with platinum and 5-fluorouracil significantly improved median OS versus the EXTREME regimen with cetuximab in the total population of HNSCC patients (13.0 months versus 10.7 months) (8). In particular, patients expressing programmed death ligand-1 (PD-L1) (85% of HNSCC patients has combined positive score ≥ 1) show an increased benefit from treatment with pembrolizumab plus platinum and 5-fluorouracil (median OS 13.6 months versus 10.4 months). However, response rates to this treatment regimen are 36% and thus still limited and comparable to the EXTREME regimen with cetuximab (8, 9). Hence, to date, management of R/M HNSCC relies on combination treatment involving platinum, 5-fluorouracil and the addition of pembrolizumab or cetuximab. However, as mentioned, only a fraction of HNSCC patients respond to these treatment regimens.

The reason for resistance to pembrolizumab treatment in HNSCC remains largely unknown. In this regard, several biomarkers, such as PD-L1 expression, immune infiltration, tumor mutational burden and immune-gene expression profiling, have been explored for their predictive potential. However, none of them could be validated in HNSCC so far (10). Concerning cetuximab, this resistance is partly attributable to lack and/or loss of sensitivity of tumor cells to EGFR inhibition, which develops during treatment and compromises the therapeutic outcome. If resistance to cetuximab therapy is present at baseline, this is defined as intrinsic (primary) resistance and can be explained by resistance-conferring factors pre-existing in the bulk of tumor cells. Moreover, nearly all patients whose tumors initially respond inevitably become acquired (secondary) resistant. Acquired resistance refers to disease progression during ongoing treatment that was initially effective (11). In these scenarios, targeting EGFR alone may not be efficacious and requires the addition of a supplementary targeting agent to maximize the therapeutic response.

Therefore, the present study aims to investigate a novel combination strategy to overcome acquired cetuximab resistance. We hypothesized that acquired cetuximab resistance in HNSCC may arise from the activation of compensatory signaling pathways following cetuximab treatment, which are able to reverse the inhibitory effects of cetuximab through phosphorylation of key proteins, thereby promoting cell survival. Pharmacological inhibition of these phosphorylated proteins might be essential to overcome acquired cetuximab resistance in HNSCC. Therefore, we first characterized the protein phosphorylation profile of two cetuximab sensitive (CetSens) HNSCC cell lines and their acquired cetuximab resistant (AcqRes) variants. Based on this protein phosphorylation profile, a novel combination treatment was designed to overcome acquired therapy resistance.

Material and Methods

Cell Culture

HPV-negative human HNSCC cell lines SC263 and SCC22b were kindly provided by Prof. Dr. Sandra Nuyts (University Hospital Leuven, Leuven, Belgium) and Prof. Dr. Olivier De Wever (Laboratory of Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium). These HNSCC cell lines were previously identified as CetSens following cetuximab treatment for 168h using the colorimetric sulforhodamine B (SRB) assay. Isogenic AcqRes HNSCC cell lines (SC263-R and SCC22b-R) were previously generated by chronically exposing these initially CetSens cell lines (parental) to cetuximab, starting with the IC50 concentration of cetuximab (12–14). In parallel, control cell lines (SC263-S and SCC22b-S) were established by exposure to the vehicle control (PBS). After 10 dose doublings, dose-response studies demonstrated that cetuximab-exposed cells developed resistance towards cetuximab (12–14). All cell lines were cultured in DMEM, supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin and 1% L-glutamine (Life Technologies, Merelbeke, Belgium). Resistant cell lines were exposed to the highest doubling dose of cetuximab every four weeks. Cells were grown as monolayers and maintained in exponential growth in 5% CO2/95% air in a humidified incubator at 37°C. All cell lines were confirmed free of mycoplasma infection through regular testing (MycoAlert Mycoplasma Detection Kit, Lonza, Verviers, Belgium). The identity of each cell line was validated through short tandem repeat profiling (Centre of Medical Genetics, University of Antwerp, Antwerp, Belgium).

Human Protein Phosphorylation Antibody Array

Human phospho-kinase antibody array kit (ARY003B, Proteome Profiler, R&D Systems, Minneapolis, MN, USA) was used to determine the relative levels of protein phosphorylation in the CetSens and AcqRes cell lines after cetuximab treatment. The human phospho-kinase antibody array was performed according to the manufacturer’s protocol. In short, cells were lysed on 6-well plates after treatment with cetuximab (0 and 100 nM, 2 hours, diluted in sterile PBS, Merck, Darmstadt, Germany). Twenty minutes before lysis, epidermal growth factor (EGF, 50 ng/ml, Sigma-Aldrich, Diegem, Belgium) was added to the medium. Protein concentrations were determined using the Pierce BCA protein kit (Thermo Scientific, Erembodegem, Belgium). Next, samples were prepared and 450 μg of proteins were incubated overnight with nitrocellulose membranes which are spotted with 46 capture antibodies in duplicate. The specific target proteins (Supplementary Table 1), if present in the sample, bind to these capture antibodies, leading to protein-antibody interactions. These protein-antibody interactions are then visualized using chemiluminescent detection reagents on the Lumi-Imager (Roche Diagnostics, Vilvoorde, Belgium). The antibodies of this kit bind to all isoforms of the target proteins and are therefore not isoform-specific. The signal is proportional to the amount phosphorylation in the bound analyte. Quantification of phosphorylation levels was executed following the manufacturer’s protocol. In short, the integrated optical density of each spot was measured and corrected for background signal using Image J software (15). Only proteins that gave rise to an integrated optical density at least 1.5-fold above background were further used for data processing. Mean integrated optical densities were obtained by averaging the integrated optical density of the duplicates on the array. The fold changes were calculated by dividing the mean integrated optical densities of the treatment and control groups.

Western Blot

In order to validate findings of the human phospho-kinase antibody array with western blot, cell lysates were three times independently prepared as described above. Twenty micrograms of proteins were separated by SDS-page (10% polyacrylamide gel, 100V, 2h) and western blot was performed (100V, 1h). Blocking of non-specific binding sites was done by incubation of the membrane with Odyssey blocking buffer TBS (Li-Cor, Leusden, The Netherlands) for 1h at room temperature while shaking. Next, primary and secondary antibody incubation and washing was performed using the SNAP id 2.0 protein detection system (Merck Millipore) according to the manufacturer’s instructions. Membranes were incubated with the following antibodies: phospho-Akt (S473) rabbit mAb (1:1000, no. 193H12, Cell Signaling Technology, Leiden, The Netherlands) and total Akt (pan) rabbit mAb (1:1000, no. 11E7, Cell Signaling Technology). Anti-β-actin was used as an internal standard (1:5000, no. A5441, Sigma Aldrich). Goat-anti-rabbit (1:10000, no. 926-32211, Li-Cor) or goat-anti-mouse (1:10000, no. 926-68070, Li-Cor) fluorescently labeled secondary antibodies were used and fluorescent detection was performed using the Odyssey imaging system (Li-Cor). Protein levels were quantified using Image Studio™ Lite, a software program available on the Odyssey imaging system. Phospho-Akt and Akt expression levels were corrected for loading differences based on beta-actin expression. Fold changes were calculated by dividing the mean fluorescent signal of the treatment and control groups.

In Silico Analysis of Akt1, Akt2 and Akt3 Expression

The baseline mRNA expression of Akt1/2/3 in HNSCC patients was examined using the RNA sequencing data from The Cancer Genome Atlas (TCGA) dataset (Provisional, 522 sequenced HNSCC patients). RNASeqV2 from TCGA was processed and normalized using the software package RNA-Seq by Expectation Maximization (RSEM) in order to generate transcripts per million. This dataset was downloaded from cBioportal.

Sulforhodamine B Assay

Cell survival was assessed using the colorimetric SRB assay, as previously described (16, 17). This assay is used for cell density determination, based on the measurement of cellular protein content, whereby it is not possible to make a distinction between inhibition of proliferation (cytostatic effect) and cell death (cytotoxic effect). Optimal seeding densities for each cell line were determined in order to ensure exponential growth during the whole duration of the assay. Cells were counted with a TC20 Automated Cell Counter (Biorad, Temse, Belgium). After overnight incubation, cells were treated with MK2206 (72h, 0-5 μM, pan-Akt inhibitor, Selleck Chemicals, Houston, USA) in combination with cetuximab (0-50 nM). Hereby, two simultaneous combination schedules were tested:

  1. Cetuximab plus MK2206 with total treatment duration of 72h

  2. Cetuximab for 168h with MK2206 added during the last 72h of treatment

MK2206 was diluted in DMSO (Merck Millipore SA/NV, Overijse, Belgium) and further dilutions were made in cell culture medium. IC50 values (i.e. drug concentration causing 50% growth inhibition) were calculated using Graphpad Prism 9 software. Possible synergism between cetuximab and MK2206 was determined by calculation of the combination index (CI) using the Additive Model as described by others (18–20). CI < 0.800, CI = 1.000 ± 0.200 and CI > 1.200 indicated synergism, additivity and antagonism, respectively.

Statistical Analysis

We performed all experiments at least three times independently, unless otherwise stated. In cytotoxicity experiments, each condition was tested in triplicate in each of the three experiments. Differences in total and phosphorylated Akt1/2/3, determined with western blot, were statistically analyzed using the non-parametric Kruskal-Wallis test. Significant values were adjusted by the Bonferroni correction for multiple testing. One-way ANOVA with Tukey-Kramer HSD posthoc analysis was used to assess significant differences in Akt1/2/3 mRNA expression of HNSCC patients (RNASeqV2 TCGA data). The influence of cetuximab treatment on the effect of MK2206 alone was evaluated for each cell line using linear mixed models in case of non-independent observations. More specifically, combination treatment was set as fixed effect. A random intercept for experimental replicates was added in order to account for the dependence of observations between experiments. The influence of cetuximab resistance status on the effect of MK2206 alone was also evaluated using linear mixed models. Resistance status was set as fixed effect and a random intercept for cell line and experimental replicates was added to account for the dependence of observations between cell lines and experiments. GraphPad Prism 9 was used for data comparison and artwork. All statistical analyses were performed in JMP Pro 15 and SPSS v25. P-values below 0.050 were considered significant.

Results

Acquired Cetuximab Resistant HNSCC Cell Lines Show Increased Phosphorylation of Akt After Cetuximab Treatment

In order to characterize acquired cetuximab resistance, a protein phosphorylation profile was established using the human phospho-kinase antibody array. Hereby, the effect of cetuximab treatment on the phosphorylation of various proteins (Supplementary Table 1) was determined in two CetSens HNSCC cell lines and their isogenic AcqRes variants. Data analysis of the protein phosphorylation profile revealed a differential response of CetSens HNSCC cell lines and AcqRes variants to cetuximab treatment. As this change was most pronounced in substrates involved in the Akt signaling pathway, we focused further on the interpretation of these results in the next paragraph.

The effects of cetuximab treatment on the phosphorylation of EGFR, Akt and other substrates involved in the Akt pathway were quantified in CetSens HNSCC cell lines and AcqRes variants (Figure 1). Following cetuximab treatment, activating phosphorylation of EGFR was decreased in all HNSCC cell lines, suggesting inhibition of EGFR signaling. Both CetSens HNSCC cell lines (i.e. SC263-S and SCC22b-S) demonstrated decreased phosphorylation of Akt1/2/3 at T308 after cetuximab treatment. T308 is phosphorylated by phosphoinositide-dependent kinase-1 (PDK1) in the phosphoinositide 3-kinase (PI3K)/Akt pathway, leading to Akt activation (21). As a result, the PI3K/Akt pathway is inhibited by cetuximab in CetSens HNSCC cell lines. In contrast, a considerable increase in Akt1/2/3 phosphorylation at T308 was observed after cetuximab treatment in both AcqRes variants. Furthermore, phosphorylation of Akt1/2/3 at S473, by mammalian target of rapamycin complex 2 (mTORC2) (21), was also enhanced in both AcqRes variants, particularly in SCC22b-R. In addition, cetuximab treatment induced an increased phosphorylation of several downstream substrates of the Akt pathway [e.g. mTOR, p70 S6 kinase, glycogen synthase kinase-3 α/ß (GSK-3α/ß), proline-rich Akt substrate 40kDa (PRAS40) and WNK lysine deficient protein kinase-1 (WNK1)] in AcqRes variants, especially in SCC22b-R. This means that the Akt pathway is still activated in AcqRes cells following cetuximab treatment, leading to anti-apoptotic and pro-proliferative effects.

Figure 1.

Figure 1

Open in a new tab

Quantification of the human phospho-kinase array blots of cetuximab sensitive (SC263-S and SCC22b-S) HNSCC cell lines and corresponding acquired cetuximab resistant (SC263-R and SCC22b-R) variants. Graph represents the fold change of selected substrates, i.e. phosphorylated EGFR, Akt1/2/3 and other substrates involved in the Akt pathway, after cetuximab treatment. Protein phosphorylation profiling was conducted with one cell lysate. The fold changes were calculated by the ratio of the mean integrated optical density (duplicates) in treatment versus control groups. Error bars were calculated based on differences between duplicates. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.

Western Blot Analysis Confirms Increased Akt1/2/3 Phosphorylation Following Cetuximab Treatment in Acquired Cetuximab Resistant HNSCC Cell Lines

Results from the protein phosphorylation profiling were first validated using western blot. Protein levels of total Akt1/2/3 and phosphorylated Akt1/2/3 at S473 were determined after cetuximab treatment in CetSens HNSCC cell lines and AcqRes variants (Figures 2A, B). Regarding the expression of total Akt 1/2/3, no change was observed following cetuximab treatment in the SC263-S and the AcqRes SC263-R variant. Cetuximab treatment resulted in a small decrease in total Akt1/2/3 in SCC22b-S, while it resulted in a considerable increase in the AcqRes variant (i.e. SCC22b-R). There was no statistical difference in the change of expression of total Akt1/2/3 following cetuximab treatment across cell lines (p = 0.130, Figure 2B). Cetuximab treatment did not induce any change in the phosphorylation of Akt1/2/3 at S473 in SC263-S, while a clear decrease in phosphorylated Akt1/2/3 was observed in SCC22b-S after cetuximab treatment. Cetuximab treatment induced a very small increase in the phosphorylation of Akt1/2/3 in SC263-R, while a considerable increase was observed in SCC22b-R. These results suggest a compensatory activation of the PI3K/Akt pathway in reaction to cetuximab treatment in Acqres variants. Statistical analysis showed a significant difference in the change of Akt1/2/3 phosphorylation at S473 after cetuximab treatment between SCC22b-S and SCC22b-R (p = 0.023), but not between SC263-S and SC263-R (p = 1.000, Figure 2B). Comparison of the results of the protein phosphorylation profiling and western blot showed good similarity between both assays. Hence, the increase in Akt1/2/3 phosphorylation after cetuximab treatment in the AcqRes HNSCC cell lines, detected with protein phosphorylation profiling, was confirmed with western blot (Figure 2C).

Figure 2.

Figure 2

Open in a new tab

Protein levels of total and phosphorylated Akt1/2/3 in cetuximab sensitive (SC263-S and SCC22b-S) HNSCC cell lines and corresponding acquired cetuximab resistant (SC263-R and SCC22b-R) variants. (A) Western blot was used to determine the levels of total and phosphorylated Akt1/2/3 (S473) after cetuximab treatment in cetuximab sensitive and acquired cetuximab resistant HNSCC cell lines. β-actin detection served as loading control. (B) Quantification of western blot results for total and phosphorylated Akt1/2/3. Signals were corrected for β-actin and the effect of cetuximab treatment is presented as fold change. Fold changes were calculated by dividing the mean fluorescent signal of the treatment and control groups. The graph represents the average fold change of three independent experiments. (C) Fold change of phosphorylated Akt1/2/3 at S473 following cetuximab treatment observed with protein phosphorylation profiling and western blot. CET, cetuximab; pAkt1/2/3, phosphorylated Akt1/2/3; *p-value ≤ 0.050. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.

In conclusion, protein phosphorylation profiling demonstrated increased phosphorylation of Akt1/2/3 after cetuximab treatment in the AcqRes HNSCC cell lines. This increase in phosphorylation was confirmed with western blot and was found significantly different between SCC22b-S and SCC22b-R. These results suggest that the combination of cetuximab with an Akt1/2/3 inhibitor might be a potential novel therapeutic combination strategy to overcome acquired cetuximab resistance in HNSCC cell lines.

HNSCC Patients Demonstrate Akt Expression

Before investigating the cytotoxic effect of the combination treatment with the EGFR inhibitor cetuximab and the Akt1/2/3 inhibitor MK2206, we determined the expression of Akt isoforms in HNSCC patients using RNA sequencing data from the TCGA dataset (Provisional, RNASeqV2 RSEM, 522 sequenced HNSCC patients). This data demonstrated that there is a significant difference in mRNA expression between Akt1, Akt2 and Akt3 (p < 0.0001, Supplementary Table 2) in HNSCC patients (Supplementary Figure 1). As substantial Akt1, Akt2 and Akt3 mRNA levels were detected in the majority of tumor samples of HNSCC patients, we can conclude that the target of MK2206 is present in HNSCC patients. Therefore, this drug can play a potential role in the treatment of HNSCC patients.

Combining Cetuximab With MK2206 Shows Additive to Synergistic Effects in HNSCC Cell Lines

Possible synergistic effects of treatment with cetuximab and MK2206 were investigated in two CetSens HNSCC cell lines and their isogenic AcqRes variants. Two simultaneous combination schedules were evaluated. First, cells were treated simultaneously for 72h with 0-5 µM MK2206 and fixed doses of cetuximab. Fixed doses of cetuximab were based on the outcome of previous monotherapy experiments with total treatment duration of 72h (data not shown). As mentioned above, we previously identified CetSens cell lines based on the outcomes of experiments with a total treatment time of 168h (14). After 72h of cetuximab treatment, there was only a limited effect on cell survival. Therefore, we chose two high concentrations of cetuximab (i.e. 25 nM and 50 nM) to use in these simultaneous combination experiments with MK2206. Based on results reported in clinical trials, these concentrations are considered clinically relevant in in vitro studies (22). Regarding MK2206, based on early phase clinical trials, clinically relevant concentrations with manageable side effects were estimated at ≤1 µM for in vitro studies (23).

The dose-response curves of the CetSens HNSCC cell lines and their AcqRes variants are shown in Figures 3A–D. A clear concentration-dependent effect of MK2206 after 72 hours of treatment was observed in all HNSCC cell lines. The IC50 values for MK2206 monotherapy ranged from 1.752 ± 0.084 µM to 4.764 ± 0.436 µM (Supplementary Figure 2A and Table 1). Acquired cetuximab resistance had no significant influence on the inhibitory potential of MK2206 (p = 0.954). Compared to MK2206 treatment alone, simultaneous treatment with cetuximab caused a significant decrease in IC50 value (p ≤ 0.048) in CetSens HNSCC cell lines and the AcqRes variants (Supplementary Figure 2A and Table 1). Furthermore, the CI ranged from 0.707 to 0.917 (Table 2). Synergy between cetuximab and 2.5 µM MK2206 was observed in two CetSens HNSCC cell lines and one AcqRes variant (i.e. in SC263-S, SC263-R and SCC22b-S with CI ≤ 0.783, Supplementary Figure 2B and Table 2) after 72h of simultaneous treatment. Combining MK2206 with higher cetuximab concentrations resulted in an increased synergistic or additive effect.

Figure 3.

Figure 3

Open in a new tab

The cytotoxic effect of cetuximab plus MK2206 with a total treatment duration of 72h. Dose-response curves for the cetuximab sensitive HNSCC cell lines SC263-S (A) and SCC22b-S (B) show a synergistic effect. Regarding the acquired cetuximab resistant variants, dose-response curves indicate a synergistic and additive effect in SC263-R (C) and SCC22b-R (D), respectively. Survival curves were corrected for the cytotoxic effect of cetuximab alone. Cells were treated with fixed concentrations of cetuximab, which were chosen based on the outcome of previous monotherapy experiments. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.

Table 1.

IC50 and standard errors for HNSCC cell lines after treatment with MK2206 plus cetuximab for 72h.

Cell line Condition IC50 MK2206 (µM) P-value
SC263-S MK2206 3.311 ± 0.537 –
MK2206 + 25 nM cetuximab 1.816 ± 0.134 0.068
MK2206 + 50 nM cetuximab 1.609 ± 0.154 0.048
SCC22b-S MK2206 3.086 ± 0.239 –
MK2206 + 25 nM cetuximab 1.749 ± 0.120 0.006
MK2206 + 50 nM cetuximab 1.646 ± 0.101 0.004
SC263-R MK2206 4.764 ± 0.436 –
MK2206 + 25 nM cetuximab 2.545 ± 0.135 0.015
MK2206 + 50 nM cetuximab 2.212 ± 0.109 0.010
SCC22b-R MK2206 1.752 ± 0.084 –
MK2206 + 25 nM cetuximab 1.446 ± 0.085 0.020
MK2206 + 50 nM cetuximab 1.327 ± 0.082 0.006
Open in a new tab

P < 0.050, significant difference in IC50 compared to MK2206 monotherapy. P < 0.050 are indicated in bold. -, cannot be calculated. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.

Table 2.

CI for HNSCC cell lines after treatment with cetuximab plus 2.5 µM MK2206 for 72h.

Cell line Condition CI
SC263-S 2.5 µM MK2206 + 25 nM cetuximab 0.775
2.5 µM MK2206 + 50 nM cetuximab 0.707
SCC22b-S 2.5 µM MK2206 + 25 nM cetuximab 0.757
2.5 µM MK2206 + 50 nM cetuximab 0.730
SC263-R 2.5 µM MK2206 + 25 nM cetuximab 0.783
2.5 µM MK2206 + 50 nM cetuximab 0.728
SCC22b-R 2.5 µM MK2206 + 25 nM cetuximab 0.937
2.5 µM MK2206 + 50 nM cetuximab 0.917
Open in a new tab

CI < 0.800, CI = 1.000 ± 0.200, and CI > 1.200 indicate synergism, additivity or antagonism, respectively. CI < 0.800 are indicated in bold. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.

Next, the cytotoxic effect of the second treatment schedule was investigated. Hereby, the cells were treated with fixed doses of cetuximab for 168h and MK2206 (0-2.5 µM) was added during the last 72h of treatment. The goal of this prolonged treatment schedule was to decrease the used drug concentrations. In contrast to the first treatment schedule, CetSens HNSCC cell lines were treated with lower concentrations of cetuximab (i.e. 0.5 nM, 1 nM and 5 nM) due to prolonged treatment duration. These fixed concentrations were based on the outcome of previous monotherapy experiments with a total treatment duration of 168h (14).

Figures 4A–D shows the dose-response curves of the CetSens HNSCC cell lines and their AcqRes variants. The addition of MK2206 during the last 72h of treatment still resulted in a concentration-dependent cytotoxic effect of this compound. The IC50 values for MK2206 ranged from 1.073 ± 0.038 µM to 4.372 ± 1.182 µM (Supplementary Figures 3A, B and Table 3). Compared to MK2206 treatment alone, simultaneous treatment with cetuximab resulted in a decrease in IC50 value (0.033 ≤ p ≤ 0.127). Furthermore, in this treatment regimen, the CI ranged from 0.578 to 0.867 (Table 4). Synergy between cetuximab and 1 µM MK2206 was observed in two CetSens HNSCC cell lines and one AcqRes variant (i.e. in SC263-S, SC263-R and SCC22b-S with CI ≤ 0.796, Supplementary Figures 3C, D and Table 4). Combining MK2206 with higher cetuximab concentrations increased the synergistic interaction in CetSens cell lines. As this synergistic effect was reached using lower concentrations of both MK2206 and cetuximab, we consider this treatment schedule as the most interesting for further investigation.

Figure 4.

Figure 4

Open in a new tab

The cytotoxic effect of cetuximab for 168h with MK2206 added during the last 72h of treatment. Dose-response curves for the cetuximab sensitive HNSCC cell lines SC263-S (A) and SCC22b-S (B) show a synergistic interaction. Regarding the acquired cetuximab resistant variants, dose-response curves indicate a synergistic and additive effect in SC263-R (C) and SCC22b-R (D), respectively. Survival curves were corrected for the cytotoxic effect of cetuximab alone. Cells were treated with fixed concentrations of cetuximab, which were based on the outcome of previous monotherapy experiments. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.

Table 3.

IC50 and standard errors for HNSCC cell lines after treatment with cetuximab for 168h with MK2206 added during the last 72h of treatment.

Cell line Condition IC50 MK2206 (µM) P-value
SC263-S MK2206 2.067 ± 0.177 –
MK2206 + 0.5 nM cetuximab 1.253 ± 0.078 0.127
MK2206 + 1 nM cetuximab 1.200 ± 0.043 0.102
MK2206 + 5 nM cetuximab 1.002 ± 0.049 0.051
SCC22b-S MK2206 3.541 ± 0.540 –
MK2206 + 0.5 nM cetuximab 1.919 ± 0.197 0.112
MK2206 + 1 nM cetuximab 1.787 ± 0.071 0.082
MK2206 + 5 nM cetuximab 1.187 ± 0.043 0.027
SC263-R MK2206 4.372 ± 1.182 –
MK2206 + 5 nM cetuximab 1.851 ± 0.315 0.045
MK2206 + 25 nM cetuximab 1.815 ± 0.201 0.054
MK2206 + 50 nM cetuximab 1.51 ± 0.264 0.090
SCC22b-R MK2206 1.073 ± 0.038 –
MK2206 + 5 nM cetuximab 0.710 ± 0.034 0.052
MK2206 + 25 nM cetuximab 0.769 ± 0.061 0.102
MK2206 + 50 nM cetuximab 0.670 ± 0.033 0.033
Open in a new tab

P < 0.050, significant difference in IC50 compared to MK2206 monotherapy. P < 0.050 are indicated in bold. -, cannot be calculated. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.

Table 4.

CI for HNSCC cell lines after treatment with cetuximab for 168h with 1 µM MK2206 added during the last 72h of treatment.

Cell line Condition CI
SC263-S 1 µM MK2206 + 0.5 nM cetuximab 0.838
1 µM MK2206 + 1 nM cetuximab 0.801
1 µM MK2206 + 5 nM cetuximab 0.732
SCC22b-S 1 µM MK2206 + 0.5 nM cetuximab 0.705
1 µM MK2206 + 1 nM cetuximab 0.688
1 µM MK2206 + 5 nM cetuximab 0.578
SC263-R 1 µM MK2206 + 5 nM cetuximab 0.805
1 µM MK2206 + 25 nM cetuximab 0.796
1 µM MK2206 + 50 nM cetuximab 0.806
SCC22b-R 1 µM MK2206 + 5 nM cetuximab 0.867
1 µM MK2206 + 25 nM cetuximab 0.865
1 µM MK2206 + 50 nM cetuximab 0.818
Open in a new tab

CI < 0.800, CI = 1.000 ± 0.200, and CI > 1.200 indicate synergism, additivity or antagonism, respectively. CI < 0.800 are indicated in bold. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.

Discussion

Targeted therapies are key for the personalized treatment of cancer patients (3). Although treatment with the EGFR-inhibitor cetuximab improves OS in HNSCC patients, therapeutic resistance poses a challenging problem and limits the success of effective anti-EGFR cancer therapies in the clinic (24). Therefore, it is of utmost importance to rationally develop novel combination strategies to overcome this therapy resistance.

Increased or sustained stimulation of EGFR mediates the activation of various signal transduction pathways. Proteins involved in these signaling pathways are potential contributors to the development of acquired resistance to drugs inhibiting EGFR signaling (25). In order to identify the signaling pathways characteristic for acquired cetuximab resistance, protein phosphorylation profiling was performed in HNSCC cell lines. This technique has already been successfully applied in other studies to identify drug resistance mechanisms (26–28). In the present study, the effect of cetuximab treatment on the phosphorylation of several proteins was determined in two CetSens HNSCC cell lines and their isogenic AcqRes variants. Based on this protein phosphorylation profiling, novel rationally designed combination strategies were investigated to overcome drug resistance.

Protein phosphorylation profiling showed a differential response of CetSens HNSCC cell lines and their AcqRes variants to EGFR inhibition by cetuximab. This profile strongly suggested that increased phosphorylation of Akt1/2/3 following cetuximab treatment is characteristic for AcqRes HNSCC cell lines. In general, CetSens HNSCC cell lines demonstrated decreased phosphorylation of EGFR (Y1086), Akt1/2/3 (T308 and S473) and downstream substrates after cetuximab treatment. Although EGFR phosphorylation was decreased, Akt1/2/3 was still phosphorylated and activated following cetuximab treatment in AcqRes HNSCC cell lines. This was supported by the observed increase in phosphorylation of several downstream substrates of Akt, such as mTOR, p70S6 kinase, GSK-3α/β, PRAS40 and WNK1. Thus, in AcqRes HNSCC cell lines, the Akt pathway was still able to exerts its anti-apoptotic and pro-proliferative effects under cetuximab treatment, possibly leading to therapy resistance. Importantly, it is worth mentioning that the number of cell lines used in this study is a limiting factor. Therefore, our data needs to be validated in additional isogenic HNSCC cell lines (and ideally in HNSCC patient samples) in order to strengthen the results. Although further confirmation in HNSCC cell lines and patient samples is still needed, based on our results, Akt represents a potential target to improve outcome of cetuximab-based treatment in HNSCC patients.

The PI3K/Akt pathway has been shown to regulate various normal biological processes, such as cellular survival, migration, proliferation, differentiation, angiogenesis, protein synthesis and glucose metabolism. Activation of Akt can be initiated by several events, mainly through a receptor-ligand interaction on the cell membrane. This receptor activation results in activation of PI3K, which phosphorylates phosphatidylinositol 3,4-biphosphate (PIP2) to generate phosphatidylinositol 3,4,5-triphosphate (PIP3). The binding of PIP3 to Akt locates Akt to the plasma membrane and allows its phosphorylation and activation by PDK1. Akt can also be phosphorylated by other substrates and in response to cellular stress, such as ischemia, hypoxia and oxidative stress. The tumor suppressor phosphatase and tensin homolog (PTEN) catalyzes the dephosphorylation of PIP3 and is the major negative regulator of Akt signaling. Activated Akt exerts its effects by phosphorylating various downstream substrates, all resulting in anti-apoptotic or pro-proliferative effects (29–32). However, the pathway is also associated with a number of oncogenic processes. Indeed, the PI3K/Akt pathway is one of the most frequently dysregulated signaling pathways in cancer, including HNSCC (33, 34).

The present study demonstrates that increased Akt activation (not isoform-specific) is characteristic for acquired cetuximab resistance in HNSCC cell lines. Importantly, this observation needs to be validated in a cohort of HNSCC patient samples in order to elucidate its clinical value. Nevertheless, previous research has already suggested that enhanced Akt activation can play a role in resistance to cetuximab, not only in HNSCC but also in colorectal cancer and non-small cell lung cancer (35–39). Increased activation of the Akt signaling pathway has been associated with genetic alterations in the PIK3CA gene (40). For instance, Rebucci et al. have demonstrated that treatment of cetuximab resistant HNSCC cells with cetuximab did not result in the decreased levels of phosphorylated Akt that were seen in cetuximab sensitive HNSCC cells. A mutation in exon 20 of the PIK3CA gene, that encodes for the catalytic p110 α subunit of PI3K, was responsible for this persistent Akt activation (36). According to the TCGA dataset, respectively 18.4% and 20.8% of HNSCC patients demonstrate PIK3CA mutations or amplification (41, 42). In addition, loss of the tumor suppressor PTEN can also lead to persistent activation of the PI3K/Akt pathway (43, 44). According to TCGA, deep and shallow deletions in the PTEN gene occur in 3.4% and 24.0% of HNSCC patients, respectively (41, 42). Based on these findings, the genetic background of the HNSCC cell lines used in this study was determined using whole-exome sequencing (data not shown). Both CetSens HNSCC cell lines and their AcqRes variants display no mutations, deletions and/or insertions in the PI3KCA and PTEN genes. As such, the persistent Akt activation in AcqRes HNSCC cell lines following cetuximab treatment cannot be explained by the genetic background of the cell lines. However, genetic alterations in PIK3CA and PTEN, possibly leading to persistent Akt activation, are present in a significant number of HNSCC patients in the TCGA cohort. Interestingly, both CetSens HNSCC cell lines and their AcqRes variants have TP53 gene mutations that are predicted to have a deleterious effect on protein function. Functional p53 inhibits the PI3K/Akt pathway by regulating the transcription of four genes, which all have an inhibitory effect on Akt and mTOR (45, 46). As a result, mutant p53 can cause sustained activation of the PI3K/Akt pathway. However, as not only AcqRes cell lines, but also CetSens cell lines display mutations in TP53, the underlying mechanism behind the observed increased phosphorylation of Akt after cetuximab treatment in AcqRes HNSCC cell lines remains unclear. To define the exact role of genetic alterations in the PI3K/Akt pathway, regarding response to cetuximab, more in-depth studies are needed with HNSCC patient samples.

As we found that increased Akt1/2/3 phosphorylation is characteristic for AcqRes HNSCC cell lines and Akt1, Akt2 and Akt3 are expressed in HNSCC patients, we hypothesized that the combination of cetuximab with an Akt inhibitor might be a potential novel therapeutic strategy to overcome acquired cetuximab resistance. To date, Akt inhibitors are not yet included in clinical practice (32). A phase II study with the pan-Akt inhibitor MK2206 in R/M HNSCC patients showed promising results (i.e. partial responses), but was not moved to phase III so far (NCT01349933). This might be due to the fact that pan-Akt inhibitors targeting all isoforms of Akt have shown to enhance the invasiveness of cancer cells in some cases. In this regard, Brolih et al. demonstrated that Akt1 inhibition leads to a more invasive phenotype in HNSCC tumors that primarily express Akt1 (47). Consistently, the latter was also observed in several studies for breast cancer (48–51). This suggests that the expression of specific Akt isoforms can influence the outcome of pharmacological Akt inhibition. Therefore, Akt isoform analysis may be necessary in order to predict the outcome of pan-Akt inhibitors (47). Alternatively, the use of isoform-selective Akt inhibitors, which have recently been developed (52), may also offer a solution to overcome the potential limitations of the pan-Akt inhibitor MK2206. On the other hand, it has been suggested that future studies should explore mechanism-based combination strategies with chemotherapy or other molecular targeted agents (53).

In the present study, our results provide a rationale to combine cetuximab with MK2206 to overcome acquired cetuximab resistance in HNSCC. To test our hypothesis, we examined the effects of treatment with cetuximab and the Akt inhibitor MK2206 in CetSens HNSCC cell lines and AcqRes variants. Hereby, two simultaneous combination schedules were tested. Synergy between cetuximab and MK2206 was observed in two CetSens HNSCC cell lines and one AcqRes variant in both simultaneous treatment schedules. An additive effect was observed in the AcqRes SCC22b-R HNSCC cell line. Interestingly, MK2206 monotherapy demonstrated already a large cytotoxic effect in the SCC22b-R cell line compared to the other three cell lines used in this study. A possible explanation is that the SCC22b-R cell line demonstrated the largest increase in phosphorylation of Akt1/2/3 in the protein phosphorylation profiling analysis. As a result, the increased cytotoxic effect of MK2206 treatment alone might explain the observed additive interaction with cetuximab. Additional research is required to further elucidate the molecular mechanisms underlying the additive to synergistic effect between cetuximab and MK2206. Overall, this study demonstrated the potential of Akt inhibition in combination treatments to overcome acquired cetuximab resistance in HNSCC.

Besides the rational design of novel combination strategies, characterization of cetuximab resistance mechanisms can also lead to the identification of predictive biomarkers. To date, no definitive biomarkers have been identified to predict the efficacy of EGFR-targeting agents in patients with HNSCC (25, 54). We found in literature that phosphorylation of Akt at S473 serves as an independent prognostic marker for radiosensitivity in advanced HNSCC and that inhibition of Akt phosphorylation with pharmacological compounds might circumvent resistance to radiotherapy (55). Moreover, it has already been reported that phosphorylated Akt might be a potential predictive biomarker for EGFR-targeted therapies. For instance, lower phosphorylated Akt was observed in cetuximab sensitive HNSCC tumors in cell line xenograft models (56). Furthermore, Lyuo et al. analyzed a cohort with 50 oral squamous cell carcinoma patients who received cetuximab-based induction chemotherapy and found that lower expression of phosphorylated Akt was associated with better disease-free survival (57). In addition, the ECOG2303 phase II trial showed that biomarker signatures consistent with activation of the PI3K/Akt pathway are associated with inferior outcomes to cetuximab-containing chemoradiotherapy regimen (37). These results encourage additional research to precisely define the role of the PI3K/Akt pathway as predictive biomarker for EGFR-targeting agents in HNSCC.

Conclusion

In conclusion, protein phosphorylation analysis demonstrated that increased Akt1/2/3 phosphorylation is characteristic for acquired cetuximab resistance in HNSCC cell lines. Furthermore, we observed an additive to synergistic interaction between the EGFR inhibitor cetuximab and the pan-Akt inhibitor MK2206 in cetuximab sensitive and acquired cetuximab resistant HNSCC cell lines. Overall, these data support the hypothesis that downstream effectors of the PI3K/Akt pathway serve as promising drug targets in the search for novel therapeutic combination strategies that are able to overcome resistance to anti-EGFR treatment in HNSCC patients.

Data Availability Statement

All data generated or analysed during this study are available from the corresponding author on reasonable request.

Ethics Statement

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author Contributions

Conceptualization, HZ, IDP, JBV, and AW. Data curation, IDP and HZ. Formal analysis, IDP and HZ. Funding acquisition, MP, FL, and AW. Investigation, IDP, HZ, and HB. Methodology, IDP and AW. Project administration, IDP, HZ, and AW. Resources, PP, FL, and AW. Supervision, IDP and AW. Visualization, IDP, HZ, and AW. Writing—original draft, IDP, and HZ. Writing—review & editing, HZ, IDP, HB, MP, JBV, FL, and AW. All authors contributed to the article and approved the submitted version.

Funding

The project was funded by Kom op tegen Kanker (Stand up to Cancer), the Flemish cancer society (OZ7410). IDP and HZ are supported by research grants of Kom op tegen Kanker (Stand up to Cancer), the Flemish cancer society (OZ7410). We would like to thank Mr. Willy Floren for funding some of the equipment used in this study.

Conflict of Interest

JBV has had in the last three years consulting/advisory relationships with Immunomedics, Innate Pharma, Merck-Serono, Merck Sharp & Dome Corp, PCI Biotech, Synthon Biopharmaceuticals, Debiopharm, Cue Biopharma, and WntResearch and has received honoraria from Merck-Serono, MSD, and BMS.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Acknowledgments

This work was performed with the support of ‘Kom op tegen Kanker’ (Stand up to Cancer), the Flemish Cancer Society.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.697967/full#supplementary-material

Supplementary Figure 1

mRNA expression level of Akt1/2/3 in HNSCC patients, available from TCGA. The graph shows the log transformed mRNA expression (mean and standard deviation) of Akt1/2/3 from 522 HNSCC patients (individual dots). This dataset (TCGA Provisional, RNASeqV2) was downloaded from cBioportal. *, p-value ≤ 0.050.

Click here for additional data file. (82.1KB, tiff)
Supplementary Figure 2

The cytotoxic effect of cetuximab plus MK2206 with a total treatment duration of 72h. (A) IC50 of MK2206 for HNSCC cell lines after treatment with MK2206 alone and in combination with cetuximab. (B) Combination index (CI) versus fraction affected (FA) plot of 2.5 μM MK2206 with fixed doses of cetuximab (25 nM and 50 nM) in SC263-S (red), SCC22b-S (blue), SC263-R (green) and SCC22b-R (orange). *, significant difference in IC50 compared to MK2206 monotherapy (p < 0.050). CI < 0.800, CI = 1.000 ± 0.200 and CI > 1.200 indicated synergism, additive effect and antagonism, respectively. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.

Click here for additional data file. (297.8KB, tiff)
Supplementary Figure 3

The cytotoxic effect of cetuximab for 168h with MK2206 added during the last 72h of treatment. (A) IC50 of MK2206 for cetuximab sensitive HNSCC cell lines after combination treatment. (B) IC50 of MK2206 for acquired cetuximab sensitive HNSCC cell lines after combination treatment. (C) Combination index (CI) versus fraction affected (FA) plot of 1 μM MK2206 with fixed doses of cetuximab (0.5 nM, 1 nM and 5 nM) in SC263-S (red) and SCC22b-S (blue). (D) Combination index (CI) versus fraction affected (FA) plot of 1 μM MK2206 with fixed doses of cetuximab (5 nM, 25 nM and 50 nM) in SC263-R (green) and SCC22b-R (orange). *, significant difference in IC50 compared to MK2206 monotherapy (p < 0.050). CI < 0.800, CI = 1.000 ± 0.200 and CI > 1.200 indicated synergism, additive effect, and antagonism, respectively. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.

Click here for additional data file. (540.8KB, tiff)
Click here for additional data file. (661.9KB, docx)
Click here for additional data file. (660.1KB, docx)

References

  • 1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68(6):394–424. doi: 10.3322/caac.21492 [DOI] [PubMed] [Google Scholar]
  • 2.Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the Global Cancer Incidence and Mortality in 2018: GLOBOCAN Sources and Methods. Int J Cancer (2019) 144(8):1941–53. doi: 10.1002/ijc.31937 [DOI] [PubMed] [Google Scholar]
  • 3.Mahipal A, Kothari N, Gupta S. Epidermal Growth Factor Receptor Inhibitors: Coming of Age. Cancer Control: J Moffitt Cancer Center (2014) 21(1):74–9. doi: 10.1177/107327481402100111 [DOI] [PubMed] [Google Scholar]
  • 4.Wieduwilt MJ, Moasser MM. The Epidermal Growth Factor Receptor Family: Biology Driving Targeted Therapeutics. Cell Mol Life Sci: CMLS (2008) 65(10):1566–84. doi: 10.1007/s00018-008-7440-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy Plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. New Engl J Med (2006) 354(6):567–78. doi: 10.1056/NEJMoa053422 [DOI] [PubMed] [Google Scholar]
  • 6.Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy Plus Cetuximab for Locoregionally Advanced Head and Neck Cancer: 5-Year Survival Data From a Phase 3 Randomised Trial, and Relation Between Cetuximab-Induced Rash and Survival. Lancet Oncol (2010) 11(1):21–8. doi: 10.1016/S1470-2045(09)70311-0 [DOI] [PubMed] [Google Scholar]
  • 7.Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-Based Chemotherapy Plus Cetuximab in Head and Neck Cancer. N Engl J Med (2008) 359(11):1116–27. doi: 10.1056/NEJMoa0802656 [DOI] [PubMed] [Google Scholar]
  • 8.Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G, Jr., et al. Pembrolizumab Alone or With Chemotherapy Versus Cetuximab With Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-048): A Randomised, Open-Label, Phase 3 Study. Lancet (London England) (2019) 394(10212):1915–28. doi: 10.1016/S0140-6736(19)32591-7.31679945 [DOI] [PubMed] [Google Scholar]
  • 9.Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, et al. The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Squamous Cell Carcinoma of the Head and Neck (HNSCC). J Immunother Cancer (2019) 7(1):184. doi: 10.1186/s40425-019-0662-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Oliva M, Spreafico A, Taberna M, Alemany L, Coburn B, Mesia R, et al. Immune Biomarkers of Response to Immune-Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma. Ann Oncol: Off J Eur Soc Med Oncol (2019) 30(1):57–67. doi: 10.1093/annonc/mdy507 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Leto SM, Trusolino L. Primary and Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer: Impact on Future Treatment Strategies. J Mol Med (Berl) (2014) 92(7):709–22. doi: 10.1007/s00109-014-1161-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Boeckx C, Blockx L, de Beeck KO, Limame R, Camp GV, Peeters M, et al. Establishment and Characterization of Cetuximab Resistant Head and Neck Squamous Cell Carcinoma Cell Lines: Focus on the Contribution of the AP-1 Transcription Factor. Am J Cancer Res (2015) 5(6):1921–38. [PMC free article] [PubMed] [Google Scholar]
  • 13.De Pauw I, Wouters A, Van den Bossche J, Deschoolmeester V, Baysal H, Pauwels P, et al. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination With Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. Cancer Biother Radiopharm (2017) 32(7):229–38. doi: 10.1089/cbr.2017.2216 [DOI] [PubMed] [Google Scholar]
  • 14.De Pauw I, Lardon F, Van den Bossche J, Baysal H, Fransen E, Deschoolmeester V, et al. Simultaneous Targeting of EGFR, HER2, and HER4 by Afatinib Overcomes Intrinsic and Acquired Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. Mol Oncol (2018) 12(6):830–54. doi: 10.1002/1878-0261.12197 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 Years of Image Analysis. Nat Methods (2012) 9(7):671–5. doi: 10.1038/nmeth.2089 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Pauwels B, Korst AE, de Pooter CM, Pattyn GG, Lambrechts HA, Baay MF, et al. Comparison of the Sulforhodamine B Assay and the Clonogenic Assay for In Vitro Chemoradiation Studies. Cancer Chemother Pharmacol (2003) 51(3):221–6. doi: 10.1007/s00280-002-0557-9 [DOI] [PubMed] [Google Scholar]
  • 17.Limame R, Wouters A, Pauwels B, Fransen E, Peeters M, Lardon F, et al. Comparative Analysis of Dynamic Cell Viability, Migration and Invasion Assessments by Novel Real-Time Technology and Classic Endpoint Assays. PloS One (2012) 7(10):e46536. doi: 10.1371/journal.pone.0046536 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Valeriote F, Lin H. Synergistic Interaction of Anticancer Agents: A Cellular Perspective. Cancer Chemother Rep (1975) 59(5):895–900. [PubMed] [Google Scholar]
  • 19.Jonsson E, Fridborg H, Nygren P, Larsson R. Synergistic Interactions of Combinations of Topotecan With Standard Drugs in Primary Cultures of Human Tumor Cells From Patients. Eur J Clin Pharmacol (1998) 54(7):509–14. doi: 10.1007/s002280050505 [DOI] [PubMed] [Google Scholar]
  • 20.Deben C, Lardon F, Wouters A, Op de Beeck K, Van den Bossche J, Jacobs J, et al. APR-246 (PRIMA-1(MET)) Strongly Synergizes With AZD2281 (Olaparib) Induced PARP Inhibition to Induce Apoptosis in non-Small Cell Lung Cancer Cell Lines. Cancer Lett (2016) 375(2):313–22. doi: 10.1016/j.canlet.2016.03.017 [DOI] [PubMed] [Google Scholar]
  • 21.Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. PhosphoSitePlus, 2014: Mutations, PTMs and Recalibrations. Nucleic Acids Res (2015) 43(Database issue):D512–20. doi: 10.1093/nar/gku1267 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Shibata K, Naito T, Okamura J, Hosokawa S, Mineta H, Kawakami J. Simple and Rapid LC-MS/MS Method for the Absolute Determination of Cetuximab in Human Serum Using an Immobilized Trypsin. J Pharm Biomed Anal (2017) 146:266–72. doi: 10.1016/j.jpba.2017.08.012 [DOI] [PubMed] [Google Scholar]
  • 23.Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, et al. First-In-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors. J Clin Oncol: Off J Am Soc Clin Oncol (2011) 29(35):4688–95. doi: 10.1200/JCO.2011.35.5263 [DOI] [PubMed] [Google Scholar]
  • 24.Cohen RB. Current Challenges and Clinical Investigations of Epidermal Growth Factor Receptor (EGFR)- and ErbB Family-Targeted Agents in the Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Cancer Treat Rev (2014) 40(4):567–77. doi: 10.1016/j.ctrv.2013.10.002 [DOI] [PubMed] [Google Scholar]
  • 25.Boeckx C, Baay M, Wouters A, Specenier P, Vermorken JB, Peeters M, et al. Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance. Oncologist (2013) 18(7):850–64. doi: 10.1634/theoncologist.2013-0013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, et al. Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in non-Small Cell Lung Cancer. PloS One (2013) 8(12):e82236. doi: 10.1371/journal.pone.0082236 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Baumgartner U, Berger F, Hashemi Gheinani A, Burgener SS, Monastyrskaya K, Vassella E. miR-19b Enhances Proliferation and Apoptosis Resistance via the EGFR Signaling Pathway by Targeting PP2A and BIM in non-Small Cell Lung Cancer. Mol Cancer (2018) 17(1):44. doi: 10.1186/s12943-018-0781-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, et al. YES1 Amplification is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical Genomics. Proc Natl Acad Sci USA (2018) 115(26):E6030–e8. doi: 10.1073/pnas.1717782115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Rogers SJ, Box C, Harrington KJ, Nutting C, Rhys-Evans P, Eccles SA. The Phosphoinositide 3-Kinase Signalling Pathway as a Therapeutic Target in Squamous Cell Carcinoma of the Head and Neck. Expert Opin Ther Targets (2005) 9(4):769–90. doi: 10.1517/14728222.9.4.769 [DOI] [PubMed] [Google Scholar]
  • 30.Engelman JA, Luo J, Cantley LC. The Evolution of Phosphatidylinositol 3-Kinases as Regulators of Growth and Metabolism. Nat Rev Genet (2006) 7(8):606–19. doi: 10.1038/nrg1879 [DOI] [PubMed] [Google Scholar]
  • 31.Vander Broek R, Mohan S, Eytan DF, Chen Z, Van Waes C. The PI3K/Akt/mTOR Axis in Head and Neck Cancer: Functions, Aberrations, Cross-Talk, and Therapies. Oral Dis (2015) 21(7):815–25. doi: 10.1111/odi.12206 [DOI] [PubMed] [Google Scholar]
  • 32.Nitulescu GM, Margina D, Juzenas P, Peng Q, Olaru OT, Saloustros E, et al. Akt Inhibitors in Cancer Treatment: The Long Journey From Drug Discovery to Clinical Use (Review). Int J Oncol (2016) 48(3):869–85. doi: 10.3892/ijo.2015.3306 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the Phosphoinositide 3-Kinase Pathway in Cancer. Nat Rev Drug Discovery (2009) 8(8):627–44. doi: 10.1038/nrd2926 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Simpson DR, Mell LK, Cohen EE. Targeting the PI3K/AKT/mTOR Pathway in Squamous Cell Carcinoma of the Head and Neck. Oral Oncol (2015) 51(4):291–8. doi: 10.1016/j.oraloncology.2014.11.012 [DOI] [PubMed] [Google Scholar]
  • 35.Silva-Oliveira RJ, Melendez M, Martinho O, Zanon MF, de Souza Viana L, Carvalho AL, et al. AKT Can Modulate the In Vitro Response of HNSCC Cells to Irreversible EGFR Inhibitors. Oncotarget (2017) 8(32):53288–301. doi: 10.1158/1538-7445.AM2017-4091 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Rebucci M, Peixoto P, Dewitte A, Wattez N, De Nuncques MA, Rezvoy N, et al. Mechanisms Underlying Resistance to Cetuximab in the HNSCC Cell Line: Role of AKT Inhibition in Bypassing This Resistance. Int J Oncol (2011) 38(1):189–200. [PubMed] [Google Scholar]
  • 37.Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, et al. Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303. Clin Cancer Res (2014) 20(11):3023–32. doi: 10.1158/1078-0432.CCR-14-0113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Yamatodani T, Ekblad L, Kjellen E, Johnsson A, Mineta H, Wennerberg J. Epidermal Growth Factor Receptor Status and Persistent Activation of Akt and P44/42 MAPK Pathways Correlate With the Effect of Cetuximab in Head and Neck and Colon Cancer Cell Lines. J Cancer Res Clin Oncol (2009) 135(3):395–402. doi: 10.1007/s00432-008-0475-2 [DOI] [PubMed] [Google Scholar]
  • 39.Kim SM, Kim JS, Kim JH, Yun CO, Kim EM, Kim HK, et al. Acquired Resistance to Cetuximab Is Mediated by Increased PTEN Instability and Leads Cross-Resistance to Gefitinib in HCC827 NSCLC Cells. Cancer Lett (2010) 296(2):150–9. doi: 10.1016/j.canlet.2010.04.006 [DOI] [PubMed] [Google Scholar]
  • 40.Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, et al. Frequent Genetic and Biochemical Alterations of the PI 3-K/AKT/PTEN Pathway in Head and Neck Squamous Cell Carcinoma. Int J Cancer J Int du Cancer (2005) 114(2):242–8. doi: 10.1002/ijc.20711 [DOI] [PubMed] [Google Scholar]
  • 41.Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The Cbio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discovery (2012) 2(5):401–4. doi: 10.1158/2159-8290.CD-12-0095 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the Cbioportal. Sci Signaling (2013) 6(269):pl1. doi: 10.1126/scisignal.2004088 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Kondo N, Tsukuda M, Taguchi T, Nakazaki K, Sakakibara A, Takahashi H, et al. Gene Status of Head and Neck Squamous Cell Carcinoma Cell Lines and Cetuximab-Mediated Biological Activities. Cancer Sci (2011) 102(9):1717–23. doi: 10.1111/j.1349-7006.2011.01999.x [DOI] [PubMed] [Google Scholar]
  • 44.Mriouah J, Boura C, Pinel S, Chretien AS, Fifre A, Merlin JL, et al. Cellular Response to Cetuximab in PTEN-Silenced Head and Neck Squamous Cell Carcinoma Cell Line. Int J Oncol (2010) 37(6):1555–63. doi: 10.3892/ijo_00000809 [DOI] [PubMed] [Google Scholar]
  • 45.Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S, et al. The Regulation of AMPK β1, TSC2, and PTEN Expression by P53: Stress, Cell and Tissue Specificity, and the Role of These Gene Products in Modulating the IGF-1-AKT-mTOR Pathways. Cancer Res (2007) 67(7):3043. doi: 10.1158/0008-5472.CAN-06-4149 [DOI] [PubMed] [Google Scholar]
  • 46.Feng Z, Zhang H, Levine AJ, Jin S. The Coordinate Regulation of the P53 and mTOR Pathways in Cells. Proc Natl Acad Sci USA (2005) 102(23):8204–9. doi: 10.1073/pnas.0502857102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Brolih S, Parks SK, Vial V, Durivault J, Mostosi L, Pouysségur J, et al. AKT1 Restricts the Invasive Capacity of Head and Neck Carcinoma Cells Harboring a Constitutively Active PI3 Kinase Activity. BMC Cancer (2018) 18(1):249. doi: 10.1186/s12885-018-4169-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Dillon RL, Marcotte R, Hennessy BT, Woodgett JR, Mills GB, Muller WJ. Akt1 and Akt2 Play Distinct Roles in the Initiation and Metastatic Phases of Mammary Tumor Progression. Cancer Res (2009) 69(12):5057–64. doi: 10.1158/0008-5472.CAN-08-4287 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt-1 (PKB-Alpha) Can Accelerate ErbB-2-Mediated Mammary Tumorigenesis But Suppresses Tumor Invasion. Cancer Res (2004) 64(9):3171–8. doi: 10.1158/0008-5472.CAN-03-3465 [DOI] [PubMed] [Google Scholar]
  • 50.Li CW, Xia W, Lim SO, Hsu JL, Huo L, Wu Y, et al. AKT1 Inhibits Epithelial-To-Mesenchymal Transition in Breast Cancer Through Phosphorylation-Dependent Twist1 Degradation. Cancer Res (2016) 76(6):1451–62. doi: 10.1158/0008-5472.CAN-15-1941 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Riggio M, Perrone MC, Polo ML, Rodriguez MJ, May M, Abba M, et al. AKT1 and AKT2 Isoforms Play Distinct Roles During Breast Cancer Progression Through the Regulation of Specific Downstream Proteins. Sci Rep (2017) 7:44244. doi: 10.1038/srep44244 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Quambusch L, Landel I, Depta L, Weisner J, Uhlenbrock N, Müller MP, et al. Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity. Angew Chem Int Ed Engl (2019) 58(52):18823–9. doi: 10.1002/anie.201909857 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, et al. Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma. Br J Haematol (2015) 171(4):463–70. doi: 10.1111/bjh.13603 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Kim BJ, Jeong JH, Kim HS, Kim JH. The Role of Anti-EGFR Agents in Patients With Locoregionally Advanced Head and Neck Cancer: A Meta-Analysis of Randomized Trials. Oncotarget (2017) 8(60):102371–80. doi: 10.18632/oncotarget.21987 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Freudlsperger C, Horn D, Weissfuss S, Weichert W, Weber KJ, Saure D, et al. Phosphorylation of AKT(Ser473) Serves as an Independent Prognostic Marker for Radiosensitivity in Advanced Head and Neck Squamous Cell Carcinoma. Int J Cancer J Int du Cancer (2015) 136(12):2775–85. doi: 10.1002/ijc.29328 [DOI] [PubMed] [Google Scholar]
  • 56.Stein AP, Swick AD, Smith MA, Blitzer GC, Yang RZ, Saha S, et al. Xenograft Assessment of Predictive Biomarkers for Standard Head and Neck Cancer Therapies. Cancer Med (2015) 4(5):699–712. doi: 10.1002/cam4.387 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Lyu J, Song H, Tian Z, Miao Y, Ren G, Guo W. Predictive Value of pAKT/PTEN Expression in Oral Squamous Cell Carcinoma Treated With Cetuximab-Based Chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol (2016) 121(1):67–72. doi: 10.1016/j.oooo.2015.09.002 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figure 1

mRNA expression level of Akt1/2/3 in HNSCC patients, available from TCGA. The graph shows the log transformed mRNA expression (mean and standard deviation) of Akt1/2/3 from 522 HNSCC patients (individual dots). This dataset (TCGA Provisional, RNASeqV2) was downloaded from cBioportal. *, p-value ≤ 0.050.

Click here for additional data file. (82.1KB, tiff)
Supplementary Figure 2

The cytotoxic effect of cetuximab plus MK2206 with a total treatment duration of 72h. (A) IC50 of MK2206 for HNSCC cell lines after treatment with MK2206 alone and in combination with cetuximab. (B) Combination index (CI) versus fraction affected (FA) plot of 2.5 μM MK2206 with fixed doses of cetuximab (25 nM and 50 nM) in SC263-S (red), SCC22b-S (blue), SC263-R (green) and SCC22b-R (orange). *, significant difference in IC50 compared to MK2206 monotherapy (p < 0.050). CI < 0.800, CI = 1.000 ± 0.200 and CI > 1.200 indicated synergism, additive effect and antagonism, respectively. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.

Click here for additional data file. (297.8KB, tiff)
Supplementary Figure 3

The cytotoxic effect of cetuximab for 168h with MK2206 added during the last 72h of treatment. (A) IC50 of MK2206 for cetuximab sensitive HNSCC cell lines after combination treatment. (B) IC50 of MK2206 for acquired cetuximab sensitive HNSCC cell lines after combination treatment. (C) Combination index (CI) versus fraction affected (FA) plot of 1 μM MK2206 with fixed doses of cetuximab (0.5 nM, 1 nM and 5 nM) in SC263-S (red) and SCC22b-S (blue). (D) Combination index (CI) versus fraction affected (FA) plot of 1 μM MK2206 with fixed doses of cetuximab (5 nM, 25 nM and 50 nM) in SC263-R (green) and SCC22b-R (orange). *, significant difference in IC50 compared to MK2206 monotherapy (p < 0.050). CI < 0.800, CI = 1.000 ± 0.200 and CI > 1.200 indicated synergism, additive effect, and antagonism, respectively. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.

Click here for additional data file. (540.8KB, tiff)
Click here for additional data file. (661.9KB, docx)
Click here for additional data file. (660.1KB, docx)

Data Availability Statement

All data generated or analysed during this study are available from the corresponding author on reasonable request.

Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES